<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002511</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-22911</org_study_id>
    <secondary_id>EORTC-22911</secondary_id>
    <secondary_id>EORTC-GU-22911</secondary_id>
    <nct_id>NCT00002511</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer</brief_title>
  <official_title>PHASE III STUDY OF POST-OPERATIVE EXTERNAL RADIOTHERAPY IN PATHOLOGICAL STAGE T3 N0 PROSTATIC CARCINOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an
      effective treatment for prostate cancer.

      PURPOSE: Randomized phase III trial to compare radiation therapy with no further treatment in
      treating patients with stage III prostate cancer following radical prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare local recurrence rates, acute and late morbidity, overall survival, disease-free
           survival, and cancer-related survival of patients with pT3 pN0 adenocarcinoma of the
           prostate randomized following radical prostatectomy to postoperative conventional pelvic
           irradiation (60 Gy) vs no further treatment until relapse.

        -  Better define the selective pathologic indications for radiotherapy in patients with pT3
           pN0 disease.

      OUTLINE: This is a randomized study.

        -  Arm I: Patients undergo radiotherapy daily, 5 days a week, for 5 weeks, followed by
           boost radiotherapy for 1-1.4 weeks.

        -  Arm II: Patients are observed. Local relapse is treated with conventional pelvic
           radiotherapy.

      Patients are followed every 3 months during the first postoperative year, every 6 months
      until the fifth year, and annually thereafter.

      PROJECTED ACCRUAL: A total of 1000 patients will be accrued for this study within 7.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1992</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">1005</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically documented invasive adenocarcinoma of the prostate staged pT3 pN0 after
             radical prostatectomy

               -  Preoperative staging must have been T0-3 N0 M0 based on physical exam, chest
                  x-ray, bone scan, CT or MRI of entire pelvis and abdomen, and serum PSA

               -  At least 1 of the following features must be present:

                    -  Complete capsule invasion (i.e., perforation)

                    -  Positive surgical margins (microscopic or gross)

                    -  Seminal vesicle invasion

          -  Radiotherapy must begin within 16 weeks following surgery, after recovery of urinary
             function

        PATIENT CHARACTERISTICS:

        Age:

          -  75 and under

        Performance status:

          -  WHO 0-2

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other malignancies

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  No more than 4 months of preoperative hormonal therapy

        Radiotherapy:

          -  Not specified

        Surgery:

          -  Radical prostatectomy required within 12 weeks with recovery of urinary function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Bolla, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Grenoble - Hopital de la Tronche</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hein van Poppel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Ganswindt U, Stenzl A, Bamberg M, Belka C. Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol. 2008 Sep;54(3):528-42. doi: 10.1016/j.eururo.2008.06.059. Epub 2008 Jun 23. Review.</citation>
    <PMID>18602742</PMID>
  </reference>
  <reference>
    <citation>Gomella LG. Re: identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. Eur Urol. 2008 Apr;53(4):855-6.</citation>
    <PMID>18441534</PMID>
  </reference>
  <reference>
    <citation>Graefen M. Words of wisdom. Re: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. Eur Urol. 2008 Mar;53(3):664-5.</citation>
    <PMID>18365318</PMID>
  </reference>
  <results_reference>
    <citation>Bolla M, Van Poppel H, Van Cangh P, et al.: Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). [Abstract] J Clin Oncol 22 (Suppl 14): A-4504, 383, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Bolla M, Van Poppel H, Van Cangh P, et al.: Post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improves progression-free survival (PFS) in pT3NO prostate cancer (PC) (EORTC 22911). [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-93, S186, 2004. Available online. Last accessed January 27, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005 Aug 13-19;366(9485):572-8.</citation>
    <PMID>16099293</PMID>
  </results_reference>
  <results_reference>
    <citation>Davis JB, Reiner B, Dusserre A, Giraud JY, Bolla M; EORTC. Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy run. Radiother Oncol. 2002 Jul;64(1):65-73.</citation>
    <PMID>12208577</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolla M, Van Poppel H, Collette L; au nom des groupes génito-urinaire et radiothérapie de l'EORTC. [Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]. Cancer Radiother. 2007 Nov;11(6-7):363-9. Epub 2007 Oct 10. French.</citation>
    <PMID>17931949</PMID>
  </results_reference>
  <results_reference>
    <citation>Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007 Sep 20;25(27):4178-86.</citation>
    <PMID>17878474</PMID>
  </results_reference>
  <results_reference>
    <citation>Tombal B, Scaillet P, Opsomer R, et al.: Immediate external beam radiation therapy (EBRT) after radical prostatectomy (PCa): long-term influence on QOL, urinary and rectal symptoms. [Abstract] American Urological Association: Annual Meeting, May 20-25, 2006, Atlanta, GA A-1599, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>van der Kwast TH, Bolla M, van Poppel H, et al.: Gleason Score and margin status are the strongest predictors for benefit of radiotherapy after radical prostatectomy. [Abstract] American Urological Association: Annual Meeting, May 20-25, 2006, Atlanta, GA A-1391, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>van der Kwast TH, Collette L, Van Poppel H, Van Cangh P, Vekemans K, DaPozzo L, Bosset JF, Kurth KH, Schröder FH, Bolla M; European Organisation for Research and Treatment of Cancer Radiotherapy and Genito-Urinary Cancer Groups. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch. 2006 Oct;449(4):428-34. Epub 2006 Aug 29.</citation>
    <PMID>16941153</PMID>
  </results_reference>
  <results_reference>
    <citation>Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, Piérart M; European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer. 2005 Nov;41(17):2662-72. Epub 2005 Oct 11.</citation>
    <PMID>16223581</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

